Rheumatoid arthritis (RA) has one of the clearest historical links between gold and modern medicine. Long before gold nanoparticles became a nanotechnology research topic, pharmaceutical gold compounds were used as disease-modifying treatments for RA.
That history is real, but it is also easy to misinterpret. Injectable gold salts, engineered gold nanoparticles and consumer colloidal gold are not interchangeable materials. Each has different chemistry, dosing, biological behaviour and evidence.
This guide examines what the research actually says about colloidal gold and rheumatoid arthritis, including the historical gold-salt trials, a small 1997 colloidal-gold study, a 2022 oral gold nanoparticle pilot, modern anti-inflammatory nanoparticle research and the limits of applying those findings to commercial colloidal gold.
If you are new to the material itself, begin with our guide to what colloidal gold is.
Quick Answer: Is Colloidal Gold Proven to Treat Rheumatoid Arthritis?
No. Consumer colloidal gold is not an established treatment for rheumatoid arthritis.
There is meaningful historical human evidence that specific pharmaceutical gold salts can reduce RA disease activity, although toxicity limited their use. There is also a small 1997 open trial of colloidal metallic gold and a 2022 study of an oral gold nanoparticle supplement that reported encouraging signals.
However, those colloidal-gold and oral-nanoparticle studies are too small and methodologically limited to establish efficacy. Most modern anti-inflammatory gold nanoparticle research remains laboratory or animal research.
Why Gold Has a Real History in Rheumatoid Arthritis Medicine
Gold therapy in rheumatology was not merely an alternative-health idea. During the 20th century, injectable gold compounds such as sodium aurothiomalate were used as disease-modifying antirheumatic drugs.
A Cochrane systematic review evaluated four randomised placebo-controlled trials involving 415 people with rheumatoid arthritis. Injectable gold produced statistically significant improvements in swollen joints, erythrocyte sedimentation rate and patient and physician assessments.
The same review also illustrates why gold therapy declined. Twenty-two percent of treated participants withdrew because of toxicity compared with 4% of controls.
So historical chrysotherapy tells us two things at once: certain gold compounds can have biologically meaningful effects in RA, and the form of gold matters enormously for safety.
Read the Cochrane review of injectable gold for rheumatoid arthritis.
Gold Salts, Gold Nanoparticles and Colloidal Gold Are Different
One of the biggest sources of confusion online is the tendency to group every form of medicinal gold together.
| Gold form | What it is | Evidence context |
|---|---|---|
| Injectable gold salts | Pharmaceutical gold compounds such as sodium aurothiomalate. | Historical randomised human RA trials show efficacy, but toxicity was a major limitation. |
| Engineered gold nanoparticles | Nanoscale gold systems produced with controlled size, surface chemistry and sometimes functional coatings. | Extensively studied in laboratory and animal inflammation research, drug delivery and nanomedicine. |
| Oral gold nanoparticle supplements | Particulate gold products formulated for oral use. | Limited human research, including a small 2022 arthritis study. |
| Commercial colloidal gold | Particles of elemental gold dispersed in liquid. | Direct clinical evidence for RA remains very limited and product-to-product characteristics can differ. |
This is why evidence from historical injections cannot simply be transferred to a bottle of colloidal gold, and why an engineered experimental nanoparticle is not automatically equivalent to a consumer supplement.
The 1997 Colloidal Gold Rheumatoid Arthritis Study
One of the earliest human reports specifically involving colloidal metallic gold was published by Guy E. Abraham and Peter B. Himmel in the Journal of Nutritional & Environmental Medicine in 1997.
The report involved 10 people with long-standing erosive rheumatoid arthritis who had not responded adequately to previous treatment. The authors reported improvements in joint tenderness and swelling during oral colloidal-gold use.
The study is sometimes dismissed online as unpublished, but that is not accurate. It was published as a journal article and has the DOI 10.1080/13590849762411.
Why It Is Still Weak Evidence
- Only 10 people were enrolled.
- There was no placebo control group.
- It was an open trial, so participants and investigators knew the treatment being used.
- The participants came from a highly selected group with severe disease.
- The findings have not been convincingly replicated in larger controlled RA trials.
It is therefore reasonable to describe the study as an interesting early clinical signal, but not as proof that colloidal gold treats rheumatoid arthritis.
The 2022 Oral Gold Nanoparticle Arthritis Study
A more recent human study published in 2022 investigated an oral gold nanoparticle supplement in 51 people with arthritis over 20 weeks. The daily dose contained 0.34 mg of elemental gold.
The study reported statistically significant improvements in several within-group Knee injury and Osteoarthritis Outcome Score measures, and some functional tests improved over time.
However, the authors also reported that the majority of objective measures did not show statistically significant improvement between the supplement and placebo groups, noting that the study lacked sufficient statistical power for many comparisons.
There are additional reasons to interpret the findings cautiously. The study included both osteoarthritis and rheumatoid arthritis rather than functioning as a dedicated RA efficacy trial. Two authors were employees of the company that supplied and funded the supplement research.
The study is therefore useful as preliminary human evidence that an oral AuNP formulation can be studied in people with arthritis, but it does not establish that colloidal gold is an effective RA therapy.
What Modern Gold Nanoparticle Research Says About Inflammation
Modern interest in gold has moved far beyond the old injectable gold salts. Researchers now engineer gold nanoparticles with different sizes, shapes and surface chemistries and study how these variables affect inflammatory biology.
A 2021 review of gold nanoparticles in autoimmune disorders described experimental work involving inflammatory cytokines, oxidative stress, immune cells and nanoparticle-based delivery systems. Much of the evidence discussed was preclinical.
More recently, a 2026 systematic review and meta-analysis examined anti-inflammatory gold nanoparticle research published from 2015 to 2026. The meta-analysis included 20 in-vivo studies and reported effects on inflammatory mediators and pathways including TNF-α, IL-1β, IL-6, NF-κB, MAPK and JAK/STAT.
That is significant mechanistic evidence for the scientific field of AuNPs. But it is crucial to understand what it does not show: the meta-analysis does not demonstrate that an over-the-counter colloidal-gold drink has been clinically proven to reduce inflammation in people with RA.
Read the 2021 autoimmune-disease review
Read the 2026 anti-inflammatory systematic review and meta-analysis.
What About the Harvard MHC Class II Research?
A frequently cited 2006 Harvard Medical School report described a mechanism by which certain medicinal metals, including a special form of gold, could interfere with MHC class II antigen presentation.
MHC class II proteins help present peptide antigens to CD4+ T cells. Because antigen presentation is central to immune activation and autoimmunity, the finding offered a plausible biochemical explanation for some actions of older medicinal gold compounds.
The underlying work was published in Nature Chemical Biology and showed noble metals stripping peptides from class II MHC proteins. The Harvard report also describes subsequent cell-culture experiments involving gold compounds.
This is valuable mechanistic science, but it should not be presented as evidence that consumer colloidal gold selectively switches off autoimmune disease. The research involved specific medicinal metal chemistry and experimental systems, not Gold Healing Colloidal Gold or a consumer oral supplementation trial.
Read the Harvard Medical School summary
View the Nature Chemical Biology publication.
The 2026 Commercial Colloidal Gold Study
An important development for the wider colloidal-gold category came in 2026, when researchers directly analysed commercially available colloidal-gold dietary supplements intended for oral consumption.
The products tested contained metallic gold nanoparticles with a reported size distribution of approximately 4 to 11 nanometres. The researchers also performed preliminary cell-based biological assessments.
This matters because it begins to narrow the gap between highly engineered laboratory AuNPs and products actually sold as colloidal-gold supplements.
However, the study did not investigate rheumatoid arthritis, joint pain or clinical anti-inflammatory outcomes. It also found cell-specific differences in toxicity and concluded that longer-term toxicological research is needed.
How Strong Is the Evidence?
| Evidence | What it tells us | How it should be interpreted |
|---|---|---|
| Injectable gold-salt RCTs | Human RA benefit was demonstrated in historical placebo-controlled trials. | Strong evidence for those pharmaceutical compounds, not for colloidal gold. Toxicity was substantial. |
| 1997 colloidal-gold study | 10-patient open trial reported improvements. | Interesting but very weak clinical evidence because of size, design and lack of replication. |
| 2022 oral AuNP study | 51 arthritis participants; some subjective and functional measures improved. | Preliminary human evidence. Underpowered for many between-group comparisons and not a dedicated RA trial. |
| AuNP inflammation research | Laboratory and animal studies show effects on inflammatory signalling and oxidative stress. | Strong mechanistic interest, but not clinical proof for consumer colloidal gold. |
| 2026 commercial colloidal study | Confirmed nanoscale metallic gold in several commercial products and assessed preliminary cell responses. | Useful product-category evidence, but it did not test RA efficacy. |
What We Can and Cannot Say About Gold and RA
What the evidence supports
- Gold has a genuine medical history in rheumatoid arthritis.
- Specific injectable gold compounds produced measurable benefit in controlled RA trials.
- Gold nanoparticles are an active area of inflammation and autoimmune-disease research.
- Small human studies of oral particulate gold have produced signals worth investigating further.
- Particle characteristics, formulation, dose and route of administration can materially change biological behaviour.
What the evidence does not currently establish
- That consumer colloidal gold is a clinically proven treatment for rheumatoid arthritis.
- That Gold Healing 60ppm Colloidal Gold reproduces the effects of historical injectable gold salts.
- That an engineered AuNP used in a laboratory can be treated as equivalent to every colloidal-gold supplement.
- That colloidal gold can replace disease-modifying antirheumatic medication or specialist rheumatology care.
Safety and Formulation Matter
Gold nanoparticle safety cannot be reduced to the statement that “gold is inert.” Nanoscale behaviour can vary with particle size, surface coating, aggregation, concentration, exposure duration and route of administration.
The historical gold-salt literature demonstrates that some gold compounds can cause clinically important toxicity. Modern nanoparticle systems are chemically different, but they also require formulation-specific safety evaluation.
The 2026 commercial-supplement study reinforces this point because different cell types responded differently to the products studied.
Anyone with rheumatoid arthritis should discuss supplements with an appropriate healthcare professional, particularly when taking prescription medicines or managing kidney, liver, immune or other chronic health conditions.
Where Colloidal Gold Fits in the Gold Healing Research Library
The most useful way to approach this subject is to separate the history of gold medicine from the emerging science of nanoscale gold.
For a broader overview of particle science, safety and experimental applications, visit the Gold Nanoparticles Research Library.
You can also explore:
- What Is Colloidal Gold?
- 20 Colloidal Gold Benefits: What Does the Science Say?
- How Colloidal Gold Is Made in the UK
If you have finished researching the category and want to compare Gold Healing's product specifications, ingredients and current ordering information, visit the Colloidal Gold UK collection or the Gold Healing 60ppm Colloidal Gold product page.
Frequently Asked Questions
Was gold really used to treat rheumatoid arthritis?
Yes. Pharmaceutical gold compounds were used as disease-modifying treatments for rheumatoid arthritis during the 20th century. Randomised trials showed benefit, although toxicity and the development of newer therapies led to a major decline in their use.
Is colloidal gold the same as the old gold injections?
No. Historical injectable gold treatments used pharmaceutical gold compounds such as sodium aurothiomalate. Colloidal gold contains particles of elemental gold dispersed in liquid. Their chemistry, dosing, pharmacology and evidence are different.
Has oral colloidal gold been studied in rheumatoid arthritis?
Yes, but the evidence is limited. A 1997 open trial involved 10 people with long-standing erosive RA and reported improvements. Because it had no placebo control and was extremely small, it cannot establish efficacy.
Have oral gold nanoparticles been studied in people with arthritis?
A 2022 study followed 51 people with osteoarthritis and rheumatoid arthritis while investigating an oral AuNP supplement. Some outcomes improved, but many objective between-group comparisons were not statistically significant and the authors noted insufficient statistical power. It should be treated as preliminary evidence.
Do gold nanoparticles reduce inflammation?
Many laboratory and animal studies report anti-inflammatory effects from specific AuNP formulations. A 2026 systematic review and meta-analysis found effects on several inflammatory pathways across in-vivo studies. That does not prove that every commercial colloidal-gold product reduces inflammation in humans.
Does the Harvard MHC-II study prove colloidal gold helps autoimmune disease?
No. The Harvard-associated research showed that certain medicinal metals, including a special form of gold, could interfere with peptide binding to MHC class II proteins in experimental systems. It helps explain a possible mechanism for medicinal gold compounds but was not a clinical trial of consumer colloidal gold.
Can colloidal gold replace rheumatoid arthritis medication?
No. Current evidence does not support replacing established rheumatoid arthritis treatment with colloidal gold. RA can cause progressive joint damage and requires appropriate medical assessment and disease management.
Scientific References
- Clark P, Tugwell P, Bennet K, et al. Injectable gold for rheumatoid arthritis. Cochrane review. PMC7045741.
- Abraham GE, Himmel PB. Management of Rheumatoid Arthritis: Rationale for the Use of Colloidal Metallic Gold. Journal of Nutritional & Environmental Medicine. 1997;7(4):295-305. DOI 10.1080/13590849762411.
- Han X, Avelar E, Mathai A, Vollmer D, Lehman R. A Clinical Study to Evaluate the Safety and Efficacy of Oral Administration of Microscopic Dose Gold Nanoparticle (AuNP) on Knee Joint Health and Function in Arthritis Patients. J Funct Morphol Kinesiol. 2022;7(3):52. PubMed PMID 35893326.
- Koushki K, et al. Gold Nanoparticles: Multifaceted Roles in the Management of Autoimmune Disorders. Biomolecules. 2021;11(9):1289. PMC8470500.
- De Wall SL, et al. Noble metals strip peptides from class II MHC proteins. Nature Chemical Biology. 2006;2:197-201. Nature Chemical Biology.
- Khan S, et al. Gold nanoparticles (AuNPs) as emerging anti-inflammatory agents: mechanisms, therapeutic advances, and future directions, a systematic review and meta-analysis. Inflammopharmacology. 2026. PubMed PMID 42489790.
- Bute OC, et al. Colloidal Gold Dietary Supplements as Nanomaterials: Physicochemical Evaluation, Estimated Oral Exposure, and Preliminary Biological Assessment. Int J Mol Sci. 2026;27(13):5872. PubMed PMID 42450145.
